Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.

ABSTRACT:

Background

Liquid biopsy is an alternative to tissue specimens for tumour genotyping. However, the frequency of genomic alterations with low circulating-tumour DNA (ctDNA) shedding is shown in pancreatic ductal adenocarcinoma (PDAC). We, therefore, investigated the prevalence of KRAS mutations and ctDNA fraction by the metastatic site in patients with PDAC.

Methods

This study enrolled previously treated PDAC patients from a plasma genomic profiling study; ctDNA analysis was performed using Guardant360 at disease progression before initiating subsequent treatment.

Results

In 512 patients with PDAC, KRAS mutations were detected in 57%. The frequency of KRAS mutation in ctDNA differed depending on the metastatic organ; among patients with single-organ metastasis (n = 296

SUBMITTER: Umemoto K 

PROVIDER: S-EPMC10070329 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature